News & Updates

Show Multimedia Only

Updating Interstitial Lung Disease from the American Thoracic Society 2025

ยา nerandomilast เป็นยาตัวใหม่ที่ยับยั้งเอนไซม์ PDE4B ช่วยต้านการเกิดพังผืดและลดการอักเสบในปอด ผลจากการศึกษา FIBRONEER-IPF ในผู้ป่วย idiopathic pulmonary fibrosis (IPF) และ FIBRONEER-ILD ในผู้ป่วย progressive pulmonary fibrosis (PPF) พบว่า ยา nerandomilast ขนาด 18 mg วันละ 2 ครั้ง สามารถชะลอการลดลงของ forced vital capacity (FVC) ได้อย่างมีนัยสำคัญเมื่อเทียบกับยาหลอก (38% ในผู้ป่วย IPF และ 41% ในผู้ป่วย PPF; p<0.001 ในทั้ง 2 กลุ่ม) และยังลดอัตราการกำเริบเฉียบพลันและอัตราตายในผู้ป่วย PPF ได้ ทั้งนี้ นอกจากยา nerandomilast จะเป็นยาต้านพังผืดตัวใหม่แล้ว ผลจากทั้งสองการศึกษายังแสดงให้เห็นว่า การใช้ยาต้านพังผืด 2 ชนิดร่วมกัน สามารถชะลอการลดลงของ FVC ได้มากกว่าการใช้ยาเพียงชนิดเดียว

Updating Interstitial Lung Disease from the American Thoracic Society 2025

8 hours ago

Upadacitinib bumps up GCA treatment armamentarium

01 Sep 2025 by

The primary results of the phase III SELECT-GCA trial underpin the potential of upadacitinib plus a glucocorticoid taper (GC-T) for the treatment of giant-cell arteritis (GCA).

Upadacitinib bumps up GCA treatment armamentarium

01 Sep 2025

7,000 steps a day may be enough

29 Aug 2025 by

Walking 7,000 steps a day can offer the same health benefits as walking 10,000 steps a day, according to a comprehensive review and meta-analysis. Experts said it could be a more realistic target than the 10,000 steps, which is traditionally seen as the benchmark to reach.

7,000 steps a day may be enough

29 Aug 2025

Exercise plus diet reduces weight, but does little to improve hip pain

28 Aug 2025

The addition of a weight-loss diet to exercise does not appear to change hip pain severity, in adults with hip osteoarthritis and overweight or obesity. However, it results in improvements in most other outcomes such as body weight and body composition.

Exercise plus diet reduces weight, but does little to improve hip pain

28 Aug 2025

Certain nonsurgical interventions for chronic low back pain may offer sustained benefits

27 Aug 2025

For individuals with chronic low back pain, nonsurgical interventions such as cognitive behavioural therapy (CBT), mindfulness, exercise, and multidisciplinary care can help reduce pain intensity and disability in the long term, according to a systematic review and meta-analysis.

Certain nonsurgical interventions for chronic low back pain may offer sustained benefits

27 Aug 2025

RA patients at high risk of degenerative valvular heart disease

24 Aug 2025

Rheumatoid arthritis (RA) may be associated with an increased risk of new-onset degenerative aortic stenosis, aortic regurgitation, and mitral regurgitation, as suggested in a study.

RA patients at high risk of degenerative valvular heart disease

24 Aug 2025

Third-line secukinumab tied to reduced survival in axSpA, axPsA

22 Aug 2025 by

A real-word study in Argentina has found poor access to secukinumab treatment among patients with public health insurance than those using the social security system or private health coverage. Furthermore, use of secukinumab as third-line therapy or higher is associated with less survival.

Third-line secukinumab tied to reduced survival in axSpA, axPsA

22 Aug 2025

Tofacitinib shows promise in TNFi-resistant Blau syndrome

19 Aug 2025

Treatment with tofacitinib demonstrates effectiveness in patients with Blau syndrome (BS) who are resistant to tumor necrosis factor inhibitors (TNFi) or corticosteroids, reports a recent study.

Tofacitinib shows promise in TNFi-resistant Blau syndrome

19 Aug 2025

Original New Drug Application Approvals by US FDA (16-31 July 2025)

19 Aug 2025

New drug applications approved by US FDA as of 16-31 July 2025 which includes New Molecular Entities (NMEs) and new biologics. It does not include Tentative Approvals. Supplemental approvals may have occurred since the original approval date.

Original New Drug Application Approvals by US FDA (16-31 July 2025)

19 Aug 2025

Frailty common in patients with vasculitis

18 Aug 2025

Frailty appears to be a familiar feature among patients with multiple forms of vasculitis, suggesting a substantial subset of patients at risk for worse outcomes, suggests a study.

Frailty common in patients with vasculitis

18 Aug 2025

News & Updates

Filter by Specialty:

Specialty:

Updating Interstitial Lung Disease from the American Thoracic Society 2025

Updating Interstitial Lung Disease from the American Thoracic Society 2025

Upadacitinib bumps up GCA treatment armamentarium

Upadacitinib bumps up GCA treatment armamentarium

7,000 steps a day may be enough

7,000 steps a day may be enough

Exercise plus diet reduces weight, but does little to improve hip pain

Exercise plus diet reduces weight, but does little to improve hip pain

Certain nonsurgical interventions for chronic low back pain may offer sustained benefits

Certain nonsurgical interventions for chronic low back pain may offer sustained benefits

RA patients at high risk of degenerative valvular heart disease

RA patients at high risk of degenerative valvular heart disease

Third-line secukinumab tied to reduced survival in axSpA, axPsA

Third-line secukinumab tied to reduced survival in axSpA, axPsA

Tofacitinib shows promise in TNFi-resistant Blau syndrome

Tofacitinib shows promise in TNFi-resistant Blau syndrome

Original New Drug Application Approvals by US FDA (16-31 July 2025)

Original New Drug Application Approvals by US FDA (16-31 July 2025)

Frailty common in patients with vasculitis

Frailty common in patients with vasculitis